Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 26A023 | Zedoresertib | 2243882-74-6 | ≧98.0% |  |
| Zedoresertib (Debio 0123) is a brain-penetrant, highly selective WEE1 kinase inhibito | ||||
| 26A020 | ZY-444 | 1802650-31-2 | ≧98.0% |  |
| ZY-444 is an anti-cancer agent by inhibiting PC ( pyruvate carboxylase ) activity. | ||||
| 25191 | Z57346765 | 1016340-64-9 | ≧98.0% |  |
| Z57346765 is a PGK1-specific inhibitor that reduces the activity of metabolic enzymes | ||||
| 25127 | Zosuquidar ( LY-335979 ) | 167354-41-8 | ≧98.0% |  |
| Zosuquidar is a potent modulator of P-glycoprotein-mediated multi-drug resistance. | ||||
| 24132 | ZINC20451377 | 2306303-35-3 | 98% Min. |  |
| ZINC20451377 is a small molecule that binds to hepatitis B surface antigen (HBsAg) wi | ||||
| 24127 | Z-LEHD-FMK | 210345-04-3 | 98% Min. |  |
| Z-LEHD-FMK is a potent, cell-permeable, and irreversible inhibitor of caspase-9. Z-LE | ||||
| 24126 | Z-IETD-FMK | 210344-98-2 | 98% Min. |  |
| MDK4982, also known as Z-IETD-FMK, is a potent, cell-permeable, irreversible inhibito | ||||
| 24125 | Z-DEVD-fmk | 210344-95-9 | 98% Min. |  |
| Z-DEVD-fmk is a cell-permeable, irreversible inhibitor of caspase-3. Caspase-3 is a c | ||||
| 24123 | Zastaprazan ( JP-1366 ) | 2133852-18-1 | ≧98.0% |  |
| Zastaprazan, also known as JP-1366, is a proton pump inhibitor. JP-1366 mediates stro | ||||
| 24104 | Zurletrectinib | 2403703-30-8 | 98% Min. |  |
| Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic age | ||||
| 24014 | Zelasudil | 2365193-22-0 | ≧98.0% |  |
| Zelasudil is a potent, highly selective and orally-active inhibitor that targets Rho- | ||||
| 24013 | Ziftomenib ( KO-539 ) | 2134675-36-6 | ≧98.0% | _2134675-36-6.png) |
| Ziftomenib is an oral, potent, and selective small molecule inhibitor that targets th | ||||
| 24012 | Zunsemetinib | 1640282-42-3 | ≧98.0% |  |
| Zunsemetinib is an investigational oral mitogen-activated protein kinase-activated pr | ||||
| 24011 | Zongertinib | 2728667-27-2 | ≧98.0% |  |
| Zongertinib [BI 1810631] is a human epidermal growth factor receptor 2 (HER2) inhibit | ||||
| 24010 | Zasocitinib | 2272904-53-5 | ≧98.0% |  |
| Zasocitinib is under development for the treatment of moderate to severe plaque psori | ||||
| 20657 | Zilurgisertib | 2173389-57-4 | ≧98.0% |  |
| Zilurgisertib (earlier known as INCB 00928) is an activin receptor-like kinase-2 (ALK | ||||
| 20651 | Zatolmilast | 1606974-33-7 | 98% Min. |  |
| Zatolmilast is a phosphodiesterase IV inhibitor. | ||||
| 20628 | Zagociguat | 2201048-82-8 | 98% Min. |  |
| Zagociguat is a guanylate cyclase activator. | ||||
| 20610 | Zavondemstat | 1851412-93-5 | ≧98.0% |  |
| Zavondemstat is a KDM4 inhibitor with potential as an antineoplastic agent. | ||||
| 20567 | 1Z105 | 1438280-73-9 | 98% Min. |  |
| 1Z105 is a TLR4/MD2 ligand, significantly reducing the IL-6 secretion by subsequent c | ||||
| 20524 | Zidesamtinib ( NVL-520 ) | 2739829-00-4 | ≧98.0% |  |
| Zidesamtinib ( NVL-520 ) is a novel brain-penetrant ROS1-selective tyrosine kinase in | ||||
| 20513 | ZINC40099027 (ZN27) | 1211825-25-0 | ≧98.0% |  |
| ZINC40099027 (ZN27) is a specific focal adhesion kinase (FAK) activator that promotes | ||||
| 20318 | Zotizalkib ( TPX-0131 ) | 2648641-36-3 | ≧98.0% | _2648641-36-3.png) |
| TPX-0131 is a next-generation ALK inhibitor drug candidate currently being evaluated | ||||
| 20317 | Zipalertinib | 1661854-97-2 | 98% Min. |  |
| Zipalertinib, also known as TAS6417, CLN-081, is a Novel EGFR Inhibitor Targeting Exo | ||||
| 20301 | ZZW-115 | 801991-87-7 | 98% Min. |  |
| ZZW-115is a potent NUPR1 inhibitor. ZZW-115 induces ferroptosis in a mitochondria-dep | ||||
| 2071629 | (3Z)-5-bromo-3-[(3-bromo-4,5-dihydroxyphenyl)methylidene]-1H-indol-2-one | 486443-73-6 | 98% Min. | -5-bromo-3-[(3-bromo-4,5-dihydroxyphenyl)methylidene]-1H-indol-2-one_486443-73-6.png) |
| LC3-mHTT-IN-AN1 (Compound AN1) is amHTT-LC3linker compound, which interacts with both | ||||
| 2071513 | ZK824859 | 2254001-81-3 | 98% Min. |  |
| ZK824859 is a potent uPA inhibitor as a potential treatment for multiple sclerosis. Z | ||||
| 204504 | Zegocractin ( CM-4620 ) | 1713240-67-5 | ≧98.0% | _1713240-67-5.png) |
| Zegocractin (CM-4620, Auxora(TM)) is a small-molecule inhibitor of the calcium releas | ||||
| 193283 | Zervimesine ( CT1812 ) | 1802632-22-9 | ≧98.0% |  |
| CT-1812 is a first-in-class, orally available sigma-2/PGRMC1 antagonist (alpha beta o | ||||
| 193281 | ZL0454 | 2229042-77-5 | >98% |  |
| ZL0454 is a potent and selective BRD4 inhibitor. ZL0454 reduces airway inflammation a | ||||